Subsidiary KPC Pharmaceuticals Warns of Sharp Profit Decline in 2025 Unaudited Results

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.

KPC Pharmaceuticals, a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported a sharp deterioration in unaudited results for 2025, with total operating revenue falling 21.72% year on year to RMB 6.58 billion and operating profit slumping 51.65%. Net profit attributable to shareholders declined 46% to RMB 349.94 million, while net profit excluding non-recurring items dropped 74.45%, underscoring significant pressure on KPC’s core earnings, although equity attributable to shareholders edged up 2.07% and net assets per share also improved slightly. The earnings weakness, reflected in a lower weighted average return on net assets of 6.58% versus 9.52% a year earlier, suggests a more challenging operating environment for KPC that could weigh on China Resources Pharmaceutical Group’s consolidated performance, given KPC’s role as a key subsidiary in the group’s China-focused pharmaceutical operations.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company with a diversified portfolio spanning the manufacture and distribution of medicines and healthcare products. Through its non-wholly owned subsidiary China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., it holds a controlling 28.05% interest in KPC Pharmaceuticals, Inc., a Shanghai-listed drug maker in mainland China, reinforcing the group’s presence in the Chinese pharmaceutical market.

Average Trading Volume: 12,510,133

Technical Sentiment Signal: Sell

Current Market Cap: HK$28.15B

See more insights into 3320 stock on TipRanks’ Stock Analysis page.